Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06046560 · ClinicalTrials.gov registry record · Phase 4
Diabetes Remote Intervention to improVe Use of Evidence-based Medications
A Phase 4 study of Diabetes and Cardiovascular Diseases, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT06046560 is a Phase 4 study of Diabetes and Cardiovascular Diseases that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 200 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06046560, a Phase 4 study of Diabetes and Cardiovascular Diseases, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
A randomized remote, implementation trial in the Mass General Brigham network was performed on 200 patients with T2D at high CV or kidney risk. The study's primary objective was to create a remote diabetes management platform that improved the initiation and adherence to glucose-lowering medications with CV and kidney benefit and was evaluated by the primary outcome: increasing the proportion of patients with prescriptions for GDMT therapy by 6 months.
Conditions Studied
Interventions
- DRUG SGLT2 inhibitor, GLP-1 RA
- BEHAVIORAL Education-First
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2021-03-22 |
| Est. Completion | 2023-07-25 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06046560
The ClinicalTrials.gov registry entry for NCT06046560 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (93% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Diabetes appearing as the primary indexed condition, and to 2 interventions - of which SGLT2 inhibitor, GLP-1 RA is the first listed.
NCT06046560 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06046560 about?
NCT06046560 is a clinical study titled "Diabetes Remote Intervention to improVe Use of Evidence-based Medications". A randomized remote, implementation trial in the Mass General Brigham network was performed on 200 patients with T2D at high CV or kidney risk. The study's primary objective was to create a remote diabetes management platform that improved the initiation and adherence to glucose-lowering medications...
What is the current status of trial NCT06046560?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2021-03-22. Estimated completion is 2023-07-25.
What conditions does trial NCT06046560 study?
This clinical trial studies the following conditions: Diabetes, Cardiovascular Diseases.
What interventions are being tested in trial NCT06046560?
The interventions under investigation include: SGLT2 inhibitor, GLP-1 RA (DRUG), Education-First (BEHAVIORAL).
Who is sponsoring clinical trial NCT06046560?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06046560 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Mechanisms of Dapagliflozin in Promoting Kidney Function and Cardiovascular Health in Kidney Transplant Recipients
RECRUITING · Phase 4
-
Efficacy of Suvorexant in the Treatment of Insomnia in Midlife Women With Pre-Diabetes
RECRUITING · Phase 4
-
Depression-Diabetes Mechanisms: Urban African Americans
COMPLETED · Phase 4
-
The Effects of Anti-Inflammatory Treatment on Insulin Resistance in Healthy Volunteers
COMPLETED · Phase 4
-
Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
COMPLETED · Phase 4
-
Preventing Depression Recurrence in Diabetes
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.